Moderna

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Moderna and other ETFs, options, and stocks.

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

CEO

Stéphane Bancel

CEOStéphane Bancel

Employees

5,600

Employees5,600

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2010

Founded2010

Employees

5,600

Employees5,600

MRNA Key Statistics

Market cap

14.66B

Market cap14.66B

Price-Earnings ratio

-6.34

Price-Earnings ratio-6.34

Dividend yield

—

Dividend yield—

Average volume

13.37M

Average volume13.37M

High today

$38.82

High today$38.82

Low today

$35.96

Low today$35.96

Open price

$36.43

Open price$36.43

Volume

6.81M

Volume6.81M

52 Week high

$170.47

52 Week high$170.47

52 Week low

$35.80

52 Week low$35.80

MRNA News

TipRanks 1d

Is Investing in Moderna Stock Simply Dead Money?

Moderna (MRNA) stock has fallen 71% over the last six months. While there’s still potential for near-term revenue tailwinds in the form of emerging infectious d...

Seeking Alpha 2d

BioNTech started at buy, Moderna at hold by Berenberg

Berenberg has initiated coverage of BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA), citing their leadership positions in mRNA medicine. The investment firm s...

TipRanks 2d

Moderna initiated with a Hold at Berenberg

Berenberg analyst Harry Gillis initiated coverage of Moderna (MRNA) with a Hold rating and $42 price target. The firm says mRNA will revolutionize the treatment...

Analyst ratings

52%

of 29 ratings

Buy

37.9%

Hold

51.7%

Sell

10.3%

More MRNA News

TipRanks 3d

Class Action Lawsuit Against Metagenomi Inc.

A class action lawsuit was filed against Metagenomi Inc. (MGX) by Levi & Korsinsky on September 26, 2024. The plaintiffs (shareholders) alleged that they bought...

Benzinga 3d

Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination

Last week, some large European and U.S. vaccine maker stocks fell in reaction to Robert F. Kennedy Jr.’s nomination to lead the Department of Health and Human S...

Seeking Alpha 3d

Moderna's stock decline after RFK Jr's appointment makes an "attractive entry point": Piper Sandler

Moderna’s (NASDAQ:MRNA) steep fall on Friday after President-elect Donald Trump selected vaccine critic Robert F. Kennedy Jr. to head the U.S. Department of Hea...

Benzinga 6d

Moderna Shares Are Dipping Today: What's Going On?

Shares of Moderna Inc. MRNA are trading lower after President-elect Donald Trump nominated Robert F. Kennedy Jr. to lead the Department of Health and Human Serv...

TipRanks 6d

Moderna and Other Vaccine Stocks Fall on News of RFK Jr. Health Nomination

Shares of vaccine makers such as Moderna (MRNA) and Novavax (NVAX) are down on news that president-elect Donald Trump has nominated Robert F. Kennedy Jr. (RFK J...

Benzinga 7d

Palantir, Moderna, Pfizer, Alibaba, Tesla: Why These 5 Stocks Are On Investors' Radars Today

The US stock market experienced a downward trend on Thursday, with both the Nasdaq Composite and the S&P 500 indices falling by nearly 0.6% respectively. The Do...

TipRanks 7d

Wolfe Research starts Moderna at Underperform, sees limited upside opportunity

Wolfe Research analyst Alexandria Hammond initiated coverage of Moderna (MRNA) with an Underperform rating and $40 price target Moderna may be the premier mRNA...